To Approve or Not to Approve: Antineoplastic Formulary Considerations
Release date: July 10, 2019
Expiration date: July 10, 2022
ACPE credit must be claimed by: July 10, 2022
Offered On-Demand only.
This webinar is also part of the 2019 ACPE Webinar Bundle
This program summarizes key considerations in the formulary review process for antineoplastics. Information highlighted will includes drug approval processes and structures within a health system, review of biosimilars compared to generic products, and clinical and economic considerations for novel antineoplastic agents when reviewing for formulary consideration. By watching this presentation, the audience will gain insight into a variety of considerations in the formulary review process and will also learn about new novel approaches to formulary drug approval.
- Describe drug approval processes for oncology medications within a health system.
- Compare/contrast the formulary drug approval process for antineoplastic generic and biosimilar agents within a health-system.
- Describe clinical and economic considerations used when evaluating novel antineoplastic agents for formulary drug approval.
- Outline novel approaches to formulary drug approval using value based frameworks.
Dina J. Benani, PharmD BCOP
Clinical Pharmacist Practitioner, Hematologic Malignancies
The Johns Hopkins Hospital
Dr. Dina Benani is a clinical pharmacist practitioner who works with the hematologic malignancies service. Dr. Benani supports the Johns Hopkins Health System Oncology Specialty Panel of the Formulary Management and Medication Use Policy Committee serving as the Specialty Panel Secretary. She received her Doctor of Pharmacy from Virginia Commonwealth University School of Pharmacy, and completed both her PGY1 Pharmacy Practice and PGY2 Oncology Pharmacy Residency Programs at the Johns Hopkins Hospital. She is board certified in Oncology Pharmacy and currently is a clinical pharmacist with the inpatient hematologic malignancies service at The Johns Hopkins Hospital. As the secretary of the Oncology Specialty Panel she helps to organize and support the panel with the ongoing review of formulary requests for antineoplastic agents as well as the review of oncology specific or related health system policies.
Celia Proctor, PharmD MBA
Assistant Director for Health System Formulary Management and Integration
The Johns Hopkins Health System
Dr. Celia Proctor the Assistant Director for Health System Formulary Management and Integration for the Johns Hopkins Health System. In her current role she is responsible for the integration of hospital formularies into one shared health system formulary and supporting pharmacy service integration strategies as a method to improve quality of patient care, improve efficiency and reduce cost. Dr. Proctor’s research interests are focused on addressing the rising cost of prescription medications, with a focus on biosimilars and limited distribution strategies. From 2016-17, she served as the President for the Maryland Society Health System Pharmacy. She received her Doctor of Pharmacy from Harding University College of Pharmacy, her M.B.A from the Johns Hopkins Carey Business School, and completed her Health System Pharmacy Administration Residency Program at the Johns Hopkins Hospital.
This activity is intended for Hematology/Oncology pharmacists. This activity has been approved for 1.00 contact hours (.10CEUs) under the ACPE universal activity number # 0465-0000-19-056-H04-P.
HOPA Member ‒ $20
Nonmember ‒ $40
The Hematology/Oncology Pharmacy Association (HOPA) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. A statement of credit will be issued only upon completion of the post-activity evaluation form and post-test. ACPE credit must be claimed by July 10, 2022.
Disclosure of Conflicts of Interest: The Hematology/Oncology Pharmacy Association (HOPA) assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CE activities. All relevant conflicts of interest that are identified are thoroughly vetted by HOPA for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. HOPA is committed to providing its learners with high-quality CE activities and related materials that promote improvements of quality in healthcare and not a specific proprietary business interest of a commercial interest.